Patent Link
January 9, 2025 – Theranib Inc., a pioneering biotech company focused on precision oncology, is proud to announce that its US patent, titled “Medicinal compound for the inhibition of aldehyde dehydrogenase subtype 1A (ALDH1A3)”, has been officially published. This milestone underscores Theranib’s commitment to transforming cancer care through groundbreaking innovation.
The patent safeguards the development and application of VE3, Theranib’s first-in-class ALDH1A3 inhibitor, designed to tackle chemotherapy resistance and metastatic progression in aggressive cancers. This achievement marks a significant step forward in ensuring the exclusivity and protection of Theranib’s intellectual property in one of the world’s largest oncology markets.
Key Highlights of the Patent:
- Covers the chemical structure, synthesis, and application of VE3 as a novel cancer therapy.
- Ensures protection for the use of VE3 in combination with standard-of-care treatments.
- Supports global patent strategy for the commercialization of VE3.
With this publication, Theranib strengthens its position as a leader in ALDH1A3-targeted therapies, advancing its mission to redefine cancer care through science and innovation.